Mission Viejo, CA, United States of America

Alissar Nehme

This inventor holds 8 USPTO granted patents and 1 published patent application, plus 4 CIPO patents and 1 EPO patent. Top assignees: Allergan, Inc., Allergan Sales, Inc.. Active years: 2002-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alissar Nehme. Retrieved from https://idiyas.com/inventor/alissar-nehme

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 1)

% Patents Active = 12.5

CIPO Patents = 4

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 2.5

ph-index = 3

Forward Citations = 68(Granted Patents)

Location History:

Newport Beach, CA (US) (2002 - 2005)
Mission Viejo, CA (US) (2014 - 2019)

Company Filing History:

Years Active: 2002-2019

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10493082 - 4-pregenen-11β-17-21-triol-3,20-dione derivatives (2019-12-03),

2. 10188667 - Pharmaceutical compositions and methods of use of 4-pregenen-11β-17-21-triol-3,20-dione derivatives (2019-01-29),

3. 9717743 - Pharmaceutical compositions and methods of use of 4-pregenen-11β-17-21-triol-3,20-dione derivatives (2017-08-01),

4. 9433631 - 4-pregenen-11β-17-21-triol-3,20-dione derivatives (2016-09-06),

5. 8906892 - 4-pregenen-11β-17-21-triol-3,20-dione derivatives (2014-12-09),

6. 8865691 - Pharmaceutical compositions and methods of use 4-pregenen-11β-17-21-triol-3,20-dione derivatives (2014-10-21),

7. 6903121 - TREATMENT OF TUMORS WITH ACETYLENES DISUBSTITUTED WITH A PHENYL OR HETEROAROMATIC GROUP AND A SUBSTITUTED CHROMANYL, THIOCHROMANYL OR TETRAHYDROQUINOLINYL GROUP IN COMBINATION WITH OTHER ANTI-TUMOR AGENTS (2005-06-07),

8. 6387950 - Treatment of tumors with RAR&agr; selective retinoid compounds in combination with other anti-tumor agents (2002-05-14),

Title: Alissar Nehme: Innovator in Pharmaceutical Sciences

Introduction

Alissar Nehme is a prominent inventor based in Mission Viejo, CA (US). She has made significant contributions to the field of pharmaceutical sciences, particularly in the development of novel compounds that modulate glucocorticoid and mineralocorticoid receptors. With a total of 8 patents to her name, her work has the potential to impact various medical treatments.

Latest Patents

Among her latest patents are the innovative 4-pregenen-11β-17-21-triol-3,20-dione derivatives. This invention relates to novel derivatives, processes for preparing them, and their use as pharmaceuticals. These compounds are specifically designed to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation. Another significant patent involves pharmaceutical compositions comprising these derivatives, aimed at treating ocular conditions linked to glucocorticoid and mineralocorticoid receptors.

Career Highlights

Alissar Nehme has worked with notable companies such as Allergan, Inc. and Allergan Sales, Inc. Her experience in these organizations has allowed her to develop her expertise in pharmaceutical innovations and contribute to the advancement of medical treatments.

Collaborations

Throughout her career, Alissar has collaborated with esteemed colleagues, including Jeffrey L. Edelman and Thomas C. Malone. These partnerships have further enriched her research and development efforts in the pharmaceutical field.

Conclusion

Alissar Nehme's contributions to pharmaceutical sciences through her innovative patents and collaborations highlight her role as a leading inventor in the industry. Her work continues to pave the way for advancements in medical treatments and therapies.

Profile summary based on public USPTO records.